Aspirin (Bayer, Ecotrin, St. Joseph, Norwich, Easprin, Zorprin)

Category:

  • Miscellaneous

Description:

  • Nonnarcotic analgesic, anti-inflammatory, antiplatelet agent, antipyretic

Indications:

  • Mild to moderated pain/fever, inflammatory conditions such as rheumatoid arthritis and osteoarthritis, rheumatic fever

  • Thromboembolic disorders

  • Reducing risk of transient ischemic attacks; reducing risk of death or nonfatal MI in patients with previous MI or unstable angina

Contraindications:

  • Hypersensitivity to salicylates, NSAIDs, or tartrazine (FDA yellow dye #5)

  • GI bleeding, hemophilia, hemorrhagic states

Precautions:

  • Pregnancy category C (D in full doses during 3rd trimester)

  • Anemia, asthma, nasal polyps, nasal allergies, hepatic disease, renal disease

  • Pre/postoperatively, children/teenagers with flu-like symptoms (may be associated with the development of Reye’s syndrome)

  • Gout, history of coagulation defects, bleeding disorders

Adverse Reactions (Side Effects):

  • CNS: confusion, dizziness, drowsiness, headache

  • EENT: dimness of vision, reversible hearing loss, tinnitus

  • GI: acute reversible hepatotoxicity, anorexia, cholestasis, dyspepsia, epigastric discomfort, GI bleeding, heartburn, nausea, increased aminase levels

  • HEME: hyperuricemia (low dose), hyperuricemia (high dose), leukopenia, prolonged bleeding time, shortened erythrocyte survival time, thrombocytopenia

  • METAB: hypoglycemia, hypokalemia, hyponatremia

  • RESP: hyperpnea, wheezing

  • SKIN: angioedema, bruising, hives, rash, urticaria

 

Dosage:

Administered orally and rectally

  • Adult:            

    • Arthritis: PO 2.6-5.2 g/day in divided doses every 4-6 hours

    • Pain/fever: PO/PR 325-650mg every 4 hours as needed, not to exceed 4g daily

    • Transient ischemic attacks:

      • 325-650mg 1-2 times daily (325mg daily may be as effective as larger doses and associated with fewer side effects)

    • MI prophylaxis: PO 165-325mg daily

  • Child:            

    • Arthritis: PO 60-90 mg/kg per day in divided doses; usually maintenance dose 80-100 mg/kg daily divided every 6-8 hours; maintain serum salicylate level of 150-300 mcg/ml

    • Pain/fever: PO/PR 10-15 mg/kg per dose every 4-6 hours as needed

Drug Interactions:

  • Methotrexate: increased serum concentration and enhanced methotrexate toxicity

  • Oral anticoagulants: increased risk of bleeding by inhibiting platelet function and possibly by producing gastric erosions

  • Warfarin: enhanced hypoprothrombinemic effect of warfarin

Note:

  • Not to be given to children with flu-like symptoms, Reye’s syndrome may develop

  • Therapeutic response may take two weeks (arthritis)

  • Administer with food

 

Home  ·  Military Medicine  ·  Sick Call  ·  Basic Exams  ·  Medical Procedures  ·  Lab and X-ray  ·  The Pharmacy  ·  The Library  ·  Equipment  ·  Patient Transport  ·  Medical Force Protection  ·  Operational Safety  ·  Operational Settings  ·  Special Operations  ·  Humanitarian Missions  ·  Instructions/Orders  ·  Other Agencies  ·  Video Gallery  ·  Forms  ·  Web Links  ·  Acknowledgements  ·  Help  ·  Feedback

Approved for public release; Distribution is unlimited.

The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.

Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.

Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300

Operational Medicine
 Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
  January 1, 2001

United States Special Operations Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323

*This web version is provided by The Brookside Associates, LLC.  It contains original contents from the official US Navy NAVMED P-5139, but has been reformatted for web access and includes advertising and links that were not present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the Department of the Navy or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. The Brookside Associates is a private organization, not affiliated with the United States Department of Defense.

© 2015, Brookside Associates, LLC. All rights reserved

Other Brookside Products

 

Advertise on this site